树突状细胞与肺癌细胞A549融合疫苗的制备及临床研究

Clinical research and preparation for dendritic cells lung cancer cells A549 fusion vaccine

目的制备树突状细胞与肺癌细胞A549融合疫苗,分析其应用效果。方法选择DC和A-549细胞,以50%聚乙二醇和10%二甲基亚砜为融合剂,构建融合细胞,观察融合效果。同时采用流式细胞仪检测相关免疫因子的变化。结果 DC细胞存活率为(90.62±5.22)%,DC-A549融合细胞融合率为(25.36±3.23)%。DC-A549融合细胞与淋巴细胞共培养的T淋巴细胞其CD8+T淋巴细胞含量高于单独培养淋巴细胞,CD4+T淋巴细胞含量低于单独培养淋巴细胞,差异有统计学意义(P<0.05)。结论树突状细胞与肺癌细胞A549融合疫苗能刺激免疫细胞活化,有可能在临床上获得抗肺癌的能力。

Objective To prepare A549 fusion vaccine of dendritic cells and lung cancer cells ,and analysis its application results .Methods Selected and DC and A-549 cell were built and the effect was observed by the 50% polyethylene glycol and 10% DMSO as the fluxing agent .While used flow cy-tometry to detect immune factors related changes .Results The DC cell viability was （90 .62 ＆#177; 5 . 22）% ,the fusion rate of DC-A549 cells was （25 .36 ＆#177; 3 .23）% .The CD8＋ T lymphocytes of the DC-A549 cells and lymphocytes were higher than those cultured alone lymphocytes ,so that was lower for the CD4＋ T lymphocytes and there were statistical significantly differences （P＆lt; 0 .05） .Conclusion Dendritic cells and A549 cells fusion vaccine has the ability to stimulate immune cell activation ,resul-ting in clinical access to anti-cancer abilities .